Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20352243 | 0.88 | ALDH1A1 (0.49) | POLBDHODHPTGESALDH1A1ALOX5 | |
| SCHEMBL282278 | 0.80 | DHODH (0.40) | DHODHKMOKMT2AALDH1A1HPGD | |
| SCHEMBL281875 | 0.80 | CHEK1 (0.42) | POLBKMT2ADYRK1AALDH1A1CYP2C9 | |
| SCHEMBL164778 | 0.78 | KMT2A (0.50) | POLBKMT2ATDP1 | |
| SCHEMBL20352579 | 0.77 | SMN1; SMN2 (0.47) | POLBDHODHALDH1A1 | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 0.77 | IGFBP3 (0.47) | POLBDHODHKMOKMT2ADYRK1A | |
| 7-Chlorokynurenic Acid SCHEMBL157187 | 0.77 | IGFBP3 (0.47) | POLBDHODHKMOKMT2ADYRK1A | |
| 7-Chlorokynurenic Acid SCHEMBL29386783 | 0.77 | IGFBP3 (0.47) | POLBDHODHKMOKMT2ADYRK1A | |
| SCHEMBL282186 | 0.76 | KDM4E (0.44) | DHODHKMOKMT2AALDH1A1HPGD | |
| 7-Chlorokynurenic Acid SCHEMBL20770380 | 0.75 | IGFBP3 (0.46) | POLBDHODHKMOKMT2ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966940-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-06 | — | — | US | disclosed |
| US-20200188332-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (CH) | 2020-06-18 | — | — | US | disclosed |
| US-20170224638-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (CH) | 2017-08-10 | — | — | US | disclosed |
| US-20170224638-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (CH) | 2017-08-10 | — | — | US | disclosed |
| US-9463168-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2016-10-11 | — | — | US | disclosed |
| US-9463168-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2016-10-11 | — | — | US | disclosed |
| CN-105837560-A | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | 埃姆比特生物科学公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105601619-A | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP | 2016-05-25 | — | — | CN | disclosed |
| US-20150265552-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (50%) (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150265552-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG (50%) (CH) | 2015-09-24 | — | — | US | disclosed |
| US-8507525-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | AURIS MEDICAL AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507525-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | AURIS MEDICAL AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-20100254907-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG | 2010-10-07 | — | — | US | disclosed |
| US-20100254907-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | AURIS MEDICAL AG | 2010-10-07 | — | — | US | disclosed |
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7589110-B2 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589110-B2 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION AND INSERM | 2007-01-18 | — | — | US | disclosed |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION AND INSERM | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | SLC1A2, GRM6, GRIK4 | POLB 4487/4885DHODH 1271/4885KMO 1337/4885 |
| US-20150265552-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | GRIK5, GRIK1, GRIK3 | POLB 3095/4885DHODH 1151/4885KMO 568/4885 |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | SLC1A2, GRM6, GRIK4 | POLB 4487/4885DHODH 1271/4885KMO 1337/4885 |
| US-20100254907-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | GRIK5, GRIK1, GRIK3 | POLB 3095/4885DHODH 1151/4885KMO 568/4885 |
| US-20200188332-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | GRIK5, GRIK1, GRIK3 | POLB 3095/4885DHODH 1151/4885KMO 568/4885 |
| US-10966940-B2 | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | GRIK5, GRIK1, GRIK3 | POLB 3095/4885DHODH 1151/4885KMO 568/4885 |
| US-20170224638-A1 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | GRIK5, GRIK1, GRIK3 | POLB 3095/4885DHODH 1151/4885KMO 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.